CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications

Zhen Huang,Christopher J. Lyon,Jin Wang,Shuihua Lu,Tony Y. Hu
DOI: https://doi.org/10.1002/advs.202301697
IF: 15.1
2023-05-12
Advanced Science
Abstract:CRISPR assays that permit sensitive detection of various new targets continue to evolve and have exciting potential for future clinical and commercial applications. However, while much has been done to improve the performance and workflows of these assays, significant challenges remain for their widespread commercial and clinical adoption, although lessons from nucleic acid amplification assays could facilitate this process. Numerous groups have employed the special properties of CRISPR/Cas systems to develop platforms that have broad potential applications for sensitive and specific detection of nucleic acid (NA) targets. However, few of these approaches have progressed to commercial or clinical applications. This review summarizes the properties of known CRISPR/Cas systems and their applications, challenges associated with the development of such assays, and opportunities to improve their performance or address unmet assay needs using nano‐/micro‐technology platforms. These include rapid and efficient sample preparation, integrated single‐tube, amplification‐free, quantifiable, multiplex, and non‐NA assays. Finally, this review discusses the current outlook for such assays, including remaining barriers for clinical or point‐of‐care applications and their commercial development.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?